Evidence map›Paper›PMID 25343000›Full record

ArticleThe open cardiovascular medicine journal2014

Gaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study.

Hisham Dokainish, Lauren Jewett, Robby Nieuwlaat, Joshua Coulson, Catherine Demers, Eva Lonn, Jeff Healey, Brian Haynes, Stuart Connolly

Open access · hybridAbstract read
In one paragraph

Article in The open cardiovascular medicine journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hisham DokainishDivision of Cardiology, Department of Medicine and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Lauren JewettDivision of Cardiology, Department of Medicine and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Robby NieuwlaatDivision of Cardiology, Department of Medicine and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Joshua CoulsonDivision of Cardiology, Department of Medicine and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Catherine DemersDivision of Cardiology, Department of Medicine and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Eva LonnDivision of Cardiology, Department of Medicine and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Jeff HealeyDivision of Cardiology, Department of Medicine and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Brian HaynesDivision of Cardiology, Department of Medicine and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Stuart ConnollyDivision of Cardiology, Department of Medicine and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
McMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess gaps between guidelines and medicine prescription/dosing and referral for defibrillator therapy in patients with left ventricular systolic dysfunction (LVSD).

methodsOutpatient echocardiography reports at an academic hospital centre were screened and outpatients with LVEF<40% were included. A questionnaire was mailed to the patients' physician, querying prescription/dosing of ACE-inhibitors (ACEi), angiotensin receptor blockers (ARB) and beta-blockers (BB). Patients with LVEF<30% had additional questions on implantable cardiac defibrillator (ICD) referral.

resultsMean age was 69.6+/-12.2 years and mean LVEF was 29.7+/-6.5%. ACEi and/or ARB prescription rate was 260/309(84.1%) versus 256/308(83.1%) for BB (p=NS for comparison). Of patients on ACEi, 77/183(42.1%) were on target dose, compared to 7/45(15.5%) for ARB and 9/254(3.5%) for BB (p<0.01). Of 171/309 patients (55.3%) with LVEF<30%, 72/171(42.1%) had an ICD and 16/171(9.4%) were referred for one.

conclusionPrescription rates of evidence-based HF medicines are relatively high in outpatients with LVSD referred for echocardiography at this Canadian academic medical centre; however, the proportion of patients at target doses was modest for ACEi and low for ARB and BB. Approximately half of patients who qualify for ICD by EF alone have one or were referred. Important reasons for patients with LVSD not on evidence-based therapy were identified.

Indexed as

EchocardiographyEvidence-based MedicineHeart FailureKnowledge TranslationLeft Ventricular DysfunctionTreatment Gaps.

Identifiers

PMID25343000
PMCPMC4205776
OpenAlexW2143483398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.